InvestSMART

Zelira Therapeutics Limited (ASX:ZLD)

ALERT: Price-sensitive ASX Announcement for ZLD
Current share price for ZLD : $0.500 -0.18 (-26.47%)+
Announcement
Release
29 Jan 2026 9:25AM
Price at Release
$0.680
Full Release
download
Summary
Zelira Therapeutics Limited reported its quarterly activities and Appendix 4C cash flow for Q2 FY2026, highlighting a transformative fundraising of US$32,981,075 into their HOPE® 1 SPV. This funding is aimed at progressing the HOPE® 1 product through the FDA clinical program, with plans to initiate Phase 1 trials and file for Orphan Drug Designation. The company received a $1,070,000 refund from the Australian Federal Government’s R&D Tax Incentive Scheme. Operating activities for the quarter generated a net cash flow of $529k, with significant reductions in research and development expenses. The company ended the quarter with a cash position of $52k. Zelira's strategic focus remains on clinical validation and commercialization of its cannabinoid-based therapeutics.
Key Points
  • Zelira raised US$32,981,075 for its HOPE® 1 SPV.
  • The fundraising is targeted at advancing the FDA clinical program.
  • Zelira received a $1,070,000 R&D Tax Incentive refund.
  • Net cash flow from operations for the quarter was $529k.
  • The company’s cash position at quarter-end was $52k.
  • Focus on clinical validation strategy and commercialization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.